Bunkerhill Health receives FDA clearance for an AI model that detects mitral annular calcification (MAC) on routine, non-gated CT scans.
Key Details
- 1Bunkerhill Health’s AI model (Bunkerhill MAC) is FDA-cleared to detect and evaluate MAC.
- 2The tool works on routine, non-gated CT scans, expanding accessibility for cardiovascular risk detection.
- 3This is the first FDA-approved AI specifically for MAC identification.
- 4Development included data from over 25 academic medical centers, including Stanford University.
- 5The algorithm is integrated into Carebricks, Bunkerhill Health’s generative AI platform.
Why It Matters
This clearance introduces a new, scalable AI solution to consistently identify a cardiovascular risk marker that can be missed in routine practice, potentially improving patient care and research. Automating MAC detection could significantly impact cardiovascular and structural heart disease assessments in radiology workflows.
Source
Cardiovascular Business
Related News
•HealthExec
New Report Highlights Clinical AI Performance, Sustainability, and Adoption Challenges
A multi-institutional review details key challenges, progress, and sustainability concerns in deploying clinical AI in real-world healthcare settings.
•Cardiovascular Business
FDA Clears AI Platform for Comprehensive Cardiac Risk Assessment on CT
HeartLung Corporation's AI-CVD receives FDA clearance for opportunistic multi-condition screening on routine chest CT scans.
•AuntMinnie
LLM Boosts Terminology Expansion in Radiology Reports Over RadLex
A large language model (LLM) significantly outperforms RadLex in expanding terms for radiology report language standardization.